跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
BEOVU - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
BEOVU
Authorized
STANDARD
BEOVU
novartis pharmaceuticals canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
ec2508ac215c6bc1
Company
novartis pharmaceuticals canada inc
Type
Standard
Approval Details
Approval Id
ec2508ac215c6bc1
Drug Approval Canada Name
BEOVU
Product Name
BEOVU
Status
Marketed
Status Date
2020-05-15
Original Market Date
2020-05-15
Din
02496976
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravitreal
Schedule
Prescription
Ahfs
52:92.00
Atc Original
S01LA06 BROLUCIZUMAB
Atc Name
s 01 la 06
Aig Number
0162094001
Company Name
novartis pharmaceuticals canada inc
Company Address
100, 700 Rue Saint-Hubert, Montreal, Quebec, Canada, H2Y 0C1
Active Ingredients
BROLUCIZUMAB
6 MG / 0.05 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
ec2508ac215c6bc1
Type
Standard
Back to Health Canada Approvals